Immunotherapy: DLBCL remissions driven by CARs
- PMID: 28352132
- DOI: 10.1038/nrclinonc.2017.48
Immunotherapy: DLBCL remissions driven by CARs
Comment on
-
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.J Clin Oncol. 2017 Jun 1;35(16):1803-1813. doi: 10.1200/JCO.2016.71.3024. Epub 2017 Mar 14. J Clin Oncol. 2017. PMID: 28291388 Free PMC article.
Similar articles
-
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.Mol Ther. 2017 Oct 4;25(10):2245-2253. doi: 10.1016/j.ymthe.2017.07.004. Epub 2017 Jul 13. Mol Ther. 2017. PMID: 28803861 Free PMC article.
-
Clinical approach to diffuse large B cell lymphoma.Blood Rev. 2016 Nov;30(6):477-491. doi: 10.1016/j.blre.2016.06.003. Epub 2016 Jun 30. Blood Rev. 2016. PMID: 27596109 Review.
-
[Molecular and histological features of diffuse large B-cell lymphoma].Magy Onkol. 2016 Jun 6;60(2):99-107. Epub 2016 Jan 28. Magy Onkol. 2016. PMID: 27275636 Review. Hungarian.
-
Novel targeted therapies in diffuse large B-cell lymphoma.Semin Hematol. 2015 Apr;52(2):126-37. doi: 10.1053/j.seminhematol.2015.01.007. Epub 2015 Jan 19. Semin Hematol. 2015. PMID: 25805592 Review.
-
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.Mol Cancer. 2015 Dec 11;14:207. doi: 10.1186/s12943-015-0474-2. Mol Cancer. 2015. PMID: 26654227 Free PMC article. Review.
References
-
- J Clin Oncol. 2017 Mar 14;:JCO2016713024 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources